4.2 Article

Persistent stromal fibroblast activation is present in chronic tendinopathy

Journal

ARTHRITIS RESEARCH & THERAPY
Volume 19, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s13075-016-1218-4

Keywords

Tendon; Tendinopathy; Inflammation; Stromal fibroblast

Categories

Funding

  1. Arthritis Research UK [20506]
  2. National Institute for Health Research (NIHR) Oxford Biomedical Research Unit
  3. National Institutes of Health Research (NIHR) [II-LB-0715-20001] Funding Source: National Institutes of Health Research (NIHR)
  4. Medical Research Council [MC_PC_14103, MC_PC_12020] Funding Source: researchfish
  5. MRC Arthritis UK Centre for MAR [Kennedy_A-TAP] Funding Source: researchfish
  6. National Institute for Health Research [NF-SI-0611-10216, II-LB-0715-20001] Funding Source: researchfish
  7. Orthopaedic Research UK [501] Funding Source: researchfish
  8. Versus Arthritis [19791, 20506] Funding Source: researchfish
  9. MRC [MC_PC_14103, MC_PC_12020] Funding Source: UKRI

Ask authors/readers for more resources

Background: Growing evidence supports a key role for inflammation in the onset and progression of tendinopathy. However, the effect of the inflammatory infiltrate on tendon cells is poorly understood. Methods: We investigated stromal fibroblast activation signatures in tissues and cells from patients with tendinopathy. Diseased tendons were collected from well-phenotyped patient cohorts with supraspinatus tendinopathy before and after sub-acromial decompression treatment. Healthy tendons were collected from patients undergoing shoulder stabilisation or anterior cruciate ligament repair. Stromal fibroblast activation markers including podoplanin (PDPN), CD106 (VCAM-1) and CD248 were investigated by immunostaining, flow cytometry and RT-qPCR. Results: PDPN, CD248 and CD106 were increased in diseased compared to healthy tendon tissues. This stromal fibroblast activation signature persisted in tendon biopsies in patients at 2-4 years post treatment. PDPN, CD248 and CD106 were increased in diseased compared to healthy tendon cells. IL-1 beta treatment induced PDPN and CD106 but not CD248. IL-1 beta treatment induced NF-kappa B target genes in healthy cells, which gradually declined following replacement with cytokine-free medium, whilst PDPN and CD106 remained above pre-stimulated levels. IL-1 beta-treated diseased cells had more profound induction of PDPN and CD106 and sustained expression of IL6 and IL8 mRNA compared to IL-1 beta-treated healthy cells. Conclusions: We conclude that stromal fibroblast activation markers are increased and persist in diseased compared to healthy tendon tissues and cells. Diseased tendon cells have distinct stromal fibroblast populations. IL-1 beta treatment induced persistent stromal fibroblast activation which was more profound in diseased cells. Persistent stromal fibroblast activation may be implicated in the development of chronic inflammation and recurrent tendinopathy. Targeting this stromal fibroblast activation signature is a potential therapeutic strategy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available